Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)
Adding atezolizumab to chemotherapy is cost-prohibitive in the US and may not be cost-effective for patients.
Authors
- Hongbin Yi (ORCID: https://orcid.org/0000-0003-2602-3959)
- Yingdan Cao (ORCID: https://orcid.org/0009-0006-7414-4674)
- Xiaoxia Wei (ORCID: https://orcid.org/0000-0003-2443-1203)
- Fenghao Shi (ORCID: https://orcid.org/0009-0008-2876-7920)
- Lina Zhu (ORCID: https://orcid.org/0000-0002-8558-2120)
- Sheng Han (ORCID: https://orcid.org/0000-0001-5975-3574)
- Huiting Lin (ORCID: https://orcid.org/0000-0001-5793-9631)
Institutions
- Fujian Medical University (CN)
- Peking University (CN)
- Fujian Provincial Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1080/14737167.2024.2422465
- Citations
- 3
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Fujian Provincial Health Technology Project